Company Filing History:
Years Active: 2025
Title: Misato Ito: Pioneering Innovations in Cancer Treatment
Introduction
Misato Ito is an innovative inventor based in Tokyo, Japan, who has made significant contributions to the field of cancer treatment. With a focus on biopharmaceuticals, Ito has invented a groundbreaking anti-human Fn14 antibody that has the potential to enhance therapeutic approaches for cancer cachexia.
Latest Patents
Misato Ito holds a patent for an anti-human Fn14 antibody that binds to human Fn14, effectively inhibiting its action. This invention aims to prevent or treat cancer cachexia, a condition characterized by severe weight loss and muscle wasting associated with cancer. The patent specifies an anti-human Fn14 antibody comprising a heavy chain with the amino acid sequence of SEQ ID NO: 2 and a light chain with the amino acid sequence of SEQ ID NO: 4.
Career Highlights
Ito serves as an influential innovator in Astellas Pharma GmbH, a renowned biopharmaceutical company. Her work in developing effective treatments showcases her commitment to addressing significant healthcare challenges, particularly in oncology.
Collaborations
In her pursuit of innovation, Misato Ito collaborates with talented professionals such as Risa Kashiwagi and Masakatsu Kawakami. Together, they contribute to research and development efforts that aim to improve patient outcomes in cancer treatment.
Conclusion
Through her dedication and pioneering inventions, Misato Ito has established herself as a key figure in the fight against cancer. With her patented anti-human Fn14 antibody, she continues to push the boundaries of medical innovation, working alongside her colleagues to make a lasting impact in the field.